Cardiff Oncology Inc (CRDF) is near the top in its industry group according to InvestorsObserver. CRDF gets an overall rating of 79. That means it scores higher than 79 percent of stocks. Cardiff Oncology Inc gets a 95 rank in the Biotechnology industry. Biotechnology is number 34 out of 148 industries.

Searching for the best stocks to invest in can be difficult. There are thousands of options and it can be confusing on what actually constitutes a great value. Investors Observer allows you to choose from eight unique metrics to view the top industries and the best performing stocks in that industry. A score of 79 would rank higher than 79 percent of all stocks.

Our proprietary scoring system captures technical factors, fundamental analysis and the opinions of analysts on Wall Street. This makes InvestorsObservers overall rating a great way to get started, regardless of your investing style. Percentile-ranked scores are also easy to understand. A score of 100 is the top and a 0 is the bottom. Theres no need to try to remember what is good for a bunch of complicated ratios, just pay attention to which numbers are the highest.

Cardiff Oncology Inc (CRDF) stock has fallen -8.95% while the S&P 500 has risen 0.6% as of 2:23 PM on Thursday, Oct 1. CRDF is down -$1.27 from the previous closing price of $14.19 on volume of 1,525,259 shares. Over the past year the S&P 500 is up 17.16% while CRDF has risen 836.23%. CRDF lost -$2.12 per share the over the last 12 months.

Click Here to get the full Stock Score Report on Cardiff Oncology Inc (CRDF) Stock.

Read more:
Is Cardiff Oncology Inc (CRDF) the Top Pick in the Biotechnology Industry? - InvestorsObserver